Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Rejects Advice To Delay Second Dose Of Pfizer Vaccine

Health Minister Says Move Not Justified By The Evidence

Executive Summary

The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine. 

You may also be interested in...



Coronavirus Notebook: EFPIA Attacks EU’s Vaccine Export Authorization Scheme, EMA Starts Rolling Review Of REGN-COV2 Antibody Combo

Médecins Sans Frontières has urged Johnson & Johnson to prioritize vaccine supplies to COVAX, the EMA has clarified the dosing interval for Pfizer/BioNTech’s Comirnaty, and the UK has ordered more vaccine from Valneva.

French HTA Body Backs Routine Six-Week Interval In COVID-19 Vaccine Dosing

France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.

Coronavirus Notebook: UK Rolls Out Ronapreve To Hospitalized Patients, Drug Safety Unit Reviews mRNA Vaccine Heart Inflammation Link

Pressure is growing on richer countries to share their excess vaccine doses, and the European Parliament has passed legislation intended to strengthen the EU’s health security framework and make joint vaccine procurement more transparent.

Topics

UsernamePublicRestriction

Register

PS143673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel